Pegylated-interferon plus ribavirin therapy in the treatment of CHC: Individualization of treatment duration according to on-treatment virologic response

Medicine and Dentistry

• Therapeutic Procedure 83%
• Treatment Duration 41%
• Genotype 41%
• Clinical Study 33%
• Chronic Hepatitis C 33%
• Ribavirin 25%
• Marker 25%
• RNA 16%
• Combination Therapy 16%
• Patient Population 16%
• Peginterferon Alpha 16%
• Individualization 8%
• Deterioration 8%
• Infection 8%
• Evaluation Study 8%
• Peginterferon 8%
• Assessment 8%
• Adjustment 8%
• Recognition 8%

Nursing and Health Professions

• Patient 100%
• Treatment Duration 41%
• Chronic Hepatitis C 33%
• Ribavirin 25%
• Marker 25%
• Combination Therapy 16%
• RNA 16%
• Inpatient 16%
• Peginterferon Alpha 16%
• Infection 8%
• Clinical Practice 8%
• Practice Guideline 8%
• Standard 8%
• Virus Load 8%
• Individualization 8%
• Peginterferon 8%
• Evaluation Study 8%
• Procedures 8%
• Dose 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Hepatitis C 33%
• Ribavirin 25%
• RNA 16%
• Peginterferon Alpha 16%
• Randomized Clinical Trial 16%
• Tolerability 8%
• Infection 8%
• Peginterferon 8%